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Abstract
Aims: To determine quality of life (QoL) outcomes after palliation of pain from bone metastases using magnetic resonance-guided high intensity focused ul-
trasound (MR-guided HIFU), measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL and the QLQ-BM22
questionnaires.
Materials and methods: Twenty patients undergoing MR-guided HIFU in an international multicentre trial self-completed the QLQ-C15-PAL and QLQ-BM22
questionnaires before and on days 7, 14, 30, 60 and 90 post-treatment. Descriptive statistics were used to represent changes in symptom and functional
scales over time and to determine their clinical signiﬁcance. QoL changes were compared in pain responders and non-responders (who were classiﬁed according
to change in worst pain score and analgesic intake, between baseline and day 30).
Results: Eighteen patients had analysable QoL data. Clinically signiﬁcant improvements were seen in the QoL scales of physical functioning, fatigue, appetite loss,
nausea and vomiting, constipation and pain in the 53% of patients who were classiﬁed as responders at day 30. No signiﬁcant changes were seen in the 47% of
patients who were non-responders at this time point.
Conclusion: Local treatment of pain from bone metastases with MR-guided HIFU, even in the presence of disseminated malignancy, has a substantial positive
effect on physical functioning, and improves other symptomatic QoL measures. This indicated a greater response to treatment over and above pain control alone.
MR-guided HIFU is non-invasive and should be considered for patients with localised metastatic bone pain and poor QoL.
 2018 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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doi.org/10.1016/j.clon.2017.12.023them experiencing chronic metastatic bone pain, which can
impact signiﬁcantly on their quality of life (QoL) [1]. When
systemic therapies are inadequate for controllingmetastatic
bone pain, external beam radiotherapy (EBRT) is offered as a
local palliative treatment [2]. This is a well-established and
effective treatment that can be delivered non-invasively in
an outpatient setting, without immediate side-effects.
However, delayed side-effects (including mucositis,
ﬁbrosis, gastrointestinal symptoms, fatigue, pathologicalis is an open access article under the CC BY license (http://creativecommons.
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D. Harding et al. / Clinical Oncology xxx (2017) 1e102fractures and neuropathies [3]) can negatively affect patient
QoL, even in the 60e80% who experience a pain response
[2]. Analysis of the Dutch Bone Metastasis study (n ¼ 956,
where >70% patients responded to treatment) [4] showed
that most QoL domains did not improve after radiotherapy.
However, several studies have reported better QoL in
radiotherapy responders than non-responders [5e7]. A
literature review of 18 studies [8] concluded that EBRT may
provide some improvement or stabilisation in QoL for those
who respond to treatment, but did not specify which areas
of QoL actually improved.
The non-invasive thermal ablation technique of mag-
netic resonance-guided high intensity focused ultrasound
(MR-guided HIFU) has growing evidence to support its ef-
ﬁcacy as a palliative treatment for painful bone metastases
[9e13], with early reports indicating that >70% of patients
with radiotherapy refractory metastatic bone pain experi-
enced signiﬁcant pain reduction within 3 months of HIFU
treatment. The largest, phase III study found that 72 of 112
patients (64%) responded to MR-guided HIFU, compared
with seven of 35 (20%) reporting a response after a sham
treatment [12]. There was a corresponding improvement of
2.4 points (out of 10) in QoL, but this was only brieﬂy
summarised using the Brief Pain Inventory Short Form (BPI-
SF), a tool that does not differentiate between the multiple
factors that inﬂuence QoL [14]. As MR-guided HIFU is
localised, there is minimal risk of toxicity to normal healthy
tissue, potentially conserving a range of QoL measures.
An International consensus panel on clinical trial end
points for bone palliation with radiotherapy recommends
the QLQ-C15-PAL [15] and the QLQ-BM22 [16] question-
naires as instruments for providing a comprehensive eval-
uation of QoL [17]. They are validated tools [18e20]
developed by the European Organization for Research and
Treatment of Cancer (EORTC). To date, no studies have used
these questionnaires to assess QoL after MR-guided HIFU
treatment. The purpose of this study, therefore, was to
determine the relationship between pain response and
speciﬁc QoL measures after MR-guided HIFU using both the
QLQ-C15-PAL and the QLQ-BM22 questionnaires.Materials and Methods
Study Population
Participants were recruited to an international, pro-
spective, single-arm study, designed to determine the efﬁ-
cacy of MR-guided HIFU for the palliation of painful skeletal
metastases (NCT01586273) [21]. Thirty-six patients with
bone metastases were assessed, of whom 20 met eligibility
criteria (worst pain 4/10 on the BPI-SF, corresponding to a
bony metastatic site accessible by MR-guided HIFU) and
received treatment between May 2012 and July 2016.
Recruitment ran across three sites: The Royal Marsden
Hospital, Sutton, UK (n ¼ 10); University Medical Centre
Utrecht, Utrecht, the Netherlands (n ¼ 5); and the Samsung
Medical Center, Seoul, South Korea (n ¼ 5). Patients at
all sites provided written informed consent, followingPlease cite this article in press as: Harding D, et al., Evaluation of Quality
with Magnetic Resonance-guided High Intensity Focused Ultrasound: A
doi.org/10.1016/j.clon.2017.12.023approval from an Institutional Review Board (REC number:
12/LO/0424, Samsung Medical Center IRB code: 2013-04-
050). The study was conducted in accordance to the prin-
ciples of the Declaration of Helsinki, Good Clinical Practice
and the study protocol. Treatments were carried out using
the Philips Sonalleve MR-guided HIFU device. Participants
were followed-up on days 7, 14, 30, 60 and 90 days after
treatment. All patients included in this QoL analysis had
previously received radiotherapy to their painful bone
metastases and had experienced differing levels of
response. Baseline patient characteristics are presented in
Table 1.
Questionnaires
Assessment of baseline QoL occurred on the day of MR-
guided HIFU treatment before treatment was adminis-
tered. A further QoL assessment was completed at each
follow-up time point. The QoL questionnaires were self-
completed by patients during their hospital visits at base-
line, 30, 60 and 90 days, and at home at the 7 and 14 day
time points.
The QLQ-C15-PAL [15] is a shortened version of the
EORTC QLQ-C30 [22] and contains 15 items. It was devel-
oped as an abbreviated tool to assess QoL in patients treated
palliatively. Data collection in advanced cancer patients is
facilitated by reducing the burden of completing the longer,
more time-consuming QLQ-C30. The QLQ-C15-PAL contains
seven symptom scales (dyspnoea, pain, insomnia, fatigue,
appetite loss, nausea and vomiting, and constipation) and
three functional scales (physical functioning, emotional
functioning, and overall QoL), which were identiﬁed as
being relevant to the palliative population.
The QLQ-BM22 [16] was developed as a speciﬁc module
for assessing QoL in patients with bone metastases. It is a
22-item questionnaire comprising two multi-item symp-
tom scales: painful sites (ﬁve items) and painful character-
istics (three items) and two multi-item functional scales:
functional interference (eight items) and psychosocial as-
pects (six items).
Items on both the QLQ-C15-PAL and QLQ-BM22 ques-
tionnaires were rated on a four-point Likert scale and were
rated from 1 (not at all) to 4 (verymuch), with the exception
of the overall QoL status item, which was rated from 1 (very
poor) to 7 (excellent). A higher score for the symptom scales
represents a higher level of symptomatology and, therefore,
a decreased QoL. By contrast, a higher score for the func-
tional scales represents a higher level of functionality and,
therefore, an increased QoL. Each scalewas transformed to a
score ranging from 0 to 100, according to their respective
scoring manual.
Magnetic Resonance-guided High Intensity Focused
Ultrasound Response Classiﬁcation
Patients were categorised as responders to MR-guided
HIFU treatment if they experienced a complete response
or a partial response at day 30 after treatment, and non-
responders if they experienced no response or painof Life Outcomes Following Palliative Treatment of Bone Metastases
n International Multicentre Study, Clinical Oncology (2017), https://
Table 1
Patient characteristics for n ¼ 18 patients who completed the QLQ-
C15-PAL and QLQ-BM22 questionnaires at baseline and at least two
other follow-up time points
Age (years)
Mean  standard deviation 55  11














Mean  standard deviation 82  8
Median (range) 80 (70e100)





Prior radiotherapy to target lesion
8 Gy 1 fraction 2 (11.1%)
20 Gy 5 fractions 3 (16.7%)
30 Gy 10 fractions 4 (22.2%)
High dose >30 Gy, or multiple
treatments
9 (50.0%)
Responder to prior radiotherapy?
(complete or partial)
7 (38.9%)
Number of months radiotherapy
to HIFU screening: median (range)
5 (1e57)
Number of painful sites (n ¼ 16)
Mean  standard deviation 2  1
Median (range) 2 (1e6)
NRS worst pain score
Mean  standard deviation 7  1
Median (range) 7 (3e9)
MEDD* (mg)
Median (range) 10 (0e1000)y
MR-guided HIFU, magnetic resonance-guided high intensity
focused ultrasound; MEDD, morphine equivalent daily dose; NRS,
numerical rating scale.
* The conversion ratios for calculating MEDD were as follows: 1
mg oral oxycodone ¼ 2 mg oral morphine, 1 mg/h fentanyl
patch ¼ 3.3 mg oral morphine, 12 mg oral codeine ¼ 1 mg oral
morphine.
y In one case, the calculatedMEDDwas>1000mg, but conversion
is inaccurate at these doses, and so the value was censored to 1000
mg.
D. Harding et al. / Clinical Oncology xxx (2017) 1e10 3progression at day 30. This was determined using the in-
ternational consensus for clinical trial end points on bone
pain palliation with radiotherapy criteria [17] whereby a
complete response was deﬁned by a BPI-SF worst pain score
of zero, with no concomitant increase in analgesic intake. A
partial response was deﬁned as a reduction of 2 (0e10
scale) in worst pain score, without analgesic increase; orPlease cite this article in press as: Harding D, et al., Evaluation of Quality
with Magnetic Resonance-guided High Intensity Focused Ultrasound: A
doi.org/10.1016/j.clon.2017.12.023analgesic reduction of 25%, without an increase in worse
pain score. Similarly, pain progression was deﬁned as an
increase of 2 in worst pain score, without analgesic
decrease; or analgesic increase of25%, with theworst pain
score stable or 1 point above baseline. No response applied
to all other cases. The  or <25% change in analgesia was
determined by calculating the change in morphine equiv-
alent daily dose [23]; for non-opioid medication where
morphine equivalent daily dose cannot be calculated, the
magnitude of reductions in dose were established through
comparison with baseline dose.
Statistical Analysis
All analyses were conducted on GraphPad Prism (version
7.00 for Windows, GraphPad Software, La Jolla, California,
USA; www.graphpad.com).
Descriptive statistics, such as mean, median and stan-
dard deviation for continuous values, and counts and pro-
portions for categorical values, were used. Normality tests,
including skewness, kurtosis and the D’Agostino-Pearson
test, were conducted for each symptom and functional scale
at baseline. Descriptive statistics were used to represent the
changes in QoL over time.
Pearson’s correlation between mean pain score as
measured by the BPI-SF and mean pain score as measured
by the QLQ-C15-PAL at baseline and day 30 was conducted
to ensure the pain level was reported consistently across
measures.
Independent sample t-tests were used to identify any
signiﬁcant differences between responders and non-
responders in each scale at baseline. For all statistical
tests, P values were considered to indicate signiﬁcance
below the 0.05 level.
Minimal clinically important differences (MCIDs) [24]
were compared against the mean change scores from
baseline at each time point and were used as thresholds for
clinically signiﬁcant improvement or deterioration. The
published MCIDs were decided based on a population of
patients completing the QLQ-C15-PAL and the QLQ-BM22 in
relation to receiving palliative radiotherapy for painful bone
metastases.Results
Data Completeness and Response Classiﬁcation
Eighteen patients completed the QoL assessment at
baseline and at least two other follow-up time points at
days 7, 14 or 30, and so were included in this QoL analysis.
Two patients were excluded as they withdrew from the
study before day 30 due to progression of underlying dis-
ease. Multi-item scales were included in analyses if at least
50% of the items included in the scale were answered. One
patient who had not completed the QLQ-BM22 at day 14
completed all other questionnaires at all other time points.
Additionally, another patient had not completed either
questionnaire at day 30. Therefore, the number ofof Life Outcomes Following Palliative Treatment of Bone Metastases
n International Multicentre Study, Clinical Oncology (2017), https://
D. Harding et al. / Clinical Oncology xxx (2017) 1e104participants at the day 30 follow-up was n ¼ 17. The same
patient did not complete the BPI-SF at the day 30 time point
and therefore their response to treatment could not be
assessed. One patient had not completed the psychosocial
aspects scale from the QLQ-BM22 at day 14, and another
patient had not completed the second side of the QLQ-C15-
PAL questionnaire at baseline and so their data were not
available for the constipation, fatigue, emotional func-
tioning and overall QoL scales at this time point, and was
not included in the determination of clinical signiﬁcance.
The number of patients remaining in the study decreased
to n ¼ 13 at the day 60 follow-up and n ¼ 11 at the day 90
follow-up.
Pain response rates (both complete and partial) to MR-
guided HIFU at days 7, 14, 30, 60 and 90 were 38.9%
(n ¼ 18), 61.1% (n ¼ 18), 53% (n ¼ 17), 61.5% (n ¼ 13) and
63.6% (n¼ 11), respectively. Therewas a signiﬁcant, positive
correlation between the QLQ-C15-PAL pain symptom scale
and the BPI-SF worst pain score at baseline (r ¼ 0.61,
P ¼ 0.008) and day 30 (r ¼ 0.62, P ¼ 0.008), meaning pain
was reported consistently across the two measures.
Six serious adverse events were reported in four of 18
patients and all were classed as being unrelated to both the
study and the treatment device.
Whole Cohort Quality of Life
Mean standard deviation scores for each symptom and
functional scale over time are presented in Table 2. All scales
were normally distributed, with the exception of the
dyspnoea and nausea and vomiting scales.
No signiﬁcant differences were found between re-
sponders’ and non-responders’ baseline scores in any
symptom scales. The baselines scores, and the trajectory of
each QoL scale over time, are presented in Figures 1 and 2.
Figure 1 displays the functioning scales from both theTable 2
Overall mean standard deviation scores for quality of life scales for 2 v
Baseline Day 7 Day
QLQ-C15-PAL
Physical functioningy 57.77  24.4 64.43  22.27 66.6
Emotional functioningy 69.62  22.6 65.76  17.11 63.4
Dyspnoea* 7.41  18.28 14.81  17.04 14.8
Pain* 66.67  17.15 59.26  20.79 54.6
Insomnia* 38.89  36.6 31.48  26.75 31.4
Fatigue* 50.32  29.71 47.53  19.75 38.2
Appetite loss* 35.19  35.19 22.22  32.34 16.6
Nausea and vomiting* 15.76  24.57 12.05  15.98 8.34
Constipation* 29.41  30.92 31.48  31.25 27.7
Overall quality of lifey 49.99  22.04 51.85  24.17 58.3
QLQ-BM22
Painful sites* 40  18.58 37.53  19.25 30.2
Painful characteristics* 43.83  20.34 41.05  17.79 39.2
Functional interferencey 45.93  18.08 55.09  14.94 58.2
Psychosocial aspectsy 54.63  18.79 59.57  16.59 57.6
* High scores represent high symptomatology/decreased quality of li
y High scores represent high functionality/increased quality of life.
Please cite this article in press as: Harding D, et al., Evaluation of Quality
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doi.org/10.1016/j.clon.2017.12.023QLQ-C15-PAL and the QLQ-BM22, for which an increase in
scores represents high functionality and improved QoL;
Figure 2 displays the symptomscales, forwhich an increase in
scores represents high symptomatology and decreased QoL.
Quality of Life in Responders to Magnetic Resonance-guided
High Intensity Focused Ultrasound
Patients classed as responders at day 30 experienced a
mean 18% increase in physical functioning at day 7. This
steadily increased to 36% by day 90, with the exception of a
small dip at day 30 to 13%. The mean scores for insomnia,
fatigue, appetite loss, nausea and vomiting, and con-
stipation all reduced by 14 points by study end, equating
to a 50%, 41%, 100%, 100% and 57% reduction in symptoms,
respectively. Dyspnoea and emotional functioning
remained relatively consistent across time points. Im-
provements in overall QoL were distinguishable by day 60,
when there was a 24% improvement in scores, which
increased to 28% at study end. This was in the context of an
improvement in pain, as measured by the QLQ-C15-PAL, by
up to 49%. There were also improvements in the painful
sites scale (>26%) and the painful characteristics scale
(>29%) in responders. The functional interference scale of
QLQ-BM22 followed a similar pattern to the physical func-
tioning scale from the QLQ-C15-PAL by showing a persistent
and gradually increasing improvement across time points,
with a slight dip in scores at day 30. Psychosocial aspect
scores remained relatively stable throughout the study.
Quality of Life in Non-responders to Magnetic Resonance-
guided High Intensity Focused Ultrasound
The QLQ-C15-PAL showed that non-responders had little
improvement in physical functioning across any of the time
points, and aworsening of physical functioning at day 30 byalidated quality of life questionnaires: QLQ-C15-PAL and QLQ-BM22
14 Day 30 Day 60 Day 90
6  21.18 59.21  30.61 65.12  26.67 72.1  25.08
4  22.52 72.56  18.33 73.08  22.85 72.74  24.73
1  20.52 9.803  15.65 15.38  17.29 9.09  15.57
3  19.64 54.9  22.64 46.15  29.78 40.91  28.25
8  24.18 31.37  32.21 25.64  24.17 21.21  16.82
6  21.65 47.06  22.43 36.75  22.42 37.36  17.43
7  26.2 29.41  33.09 12.82  21.68 9.091  21.56
 13.11 15.69  23.18 5.14  8.02 0  0
8  32.84 17.65  29.15 12.82  28.99 21.21  34.23
3  22.31 50.98  24.62 56.41  25.02 56.07  27.14
 15.83 31.76  15.19 32.31  16.29 34.55  21.04
1  16.25 38.56  18.48 33.33  20.29 31.31  15.57
6  15.92 52.24  24.64 59.8  27.53 63.15  23.29
4  15.96 52.94  25.09 55.56  17.57 55.05  18.17
fe.
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Fig 1. Graphs representing changes between responders and non-responders in each QLQ-BM22 and QLQ-C15-PAL functional scale over time.
The vertical axis is the mean score and the horizontal axis is the study time point. Error bars show standard error of the mean (SEM). Higher
scores represent high functionality, i.e. increased quality of life.
D. Harding et al. / Clinical Oncology xxx (2017) 1e10 520%. The mean scores for the insomnia, appetite loss and
nausea and vomiting scales had improved by 10 points by
the study end, equating to a 29%, 40% and 100% reduction in
symptoms, respectively. However, scores were consistently
worse than those of the responders at each follow-up time
point, with the exception of the nausea and vomitingPlease cite this article in press as: Harding D, et al., Evaluation of Quality
with Magnetic Resonance-guided High Intensity Focused Ultrasound: A
doi.org/10.1016/j.clon.2017.12.023response scale at day 7. The fatigue scale remained rela-
tively constant throughout the study, with a small wors-
ening of 9% by day 90. There was also a substantial (40%)
worsening in constipation scores at study end. Emotional
functioning saw a 6% worsening in scores by day 90,
compared with a 9% improvement seen in responders. Inof Life Outcomes Following Palliative Treatment of Bone Metastases
n International Multicentre Study, Clinical Oncology (2017), https://
D. Harding et al. / Clinical Oncology xxx (2017) 1e106
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D. Harding et al. / Clinical Oncology xxx (2017) 1e10 7terms of overall QoL there were no notable changes, with a
small decrease (7%) by study end. Although pain scores
remained relatively constant for non-responders up to day
60, there was an improvement at day 90 by 33%. Using the
QLQ-BM22, non-responders saw a 15% worsening in painful
sites scores by day 90. The 22% improvement in painful
characteristics scores at study end was preceded by a
consistent worsening of scores by an average of 27%. The
functional interference and psychosocial aspects scales
remained relatively constant throughout, reﬂecting similar
trends as in the physical and emotional functioning scales
seen in the QLQ-C15-PAL for non-responders.
Comparison against Minimal Clinically Important
Differences
Table 3 compares the QoL change scores in responders
versus non-responders with the distribution-based MCIDs
[24]. Clinically signiﬁcant improvements were seen in re-
sponders in the fatigue, appetite loss, nausea, constipation
and physical functioning scales of the QLQ-C15-PAL, and
within the painful sites, painful characteristics and func-
tional interference scales of the QLQ-BM22. Responders had
no signiﬁcant deterioration on any scale. Non-responders
saw no clinically signiﬁcant improvements in QoL scales,
with the exception of the pain scale at day 90, and saw
clinically signiﬁcant deterioration in the physical func-
tioning and painful characteristics scales at one time point
each.Discussion
Our study shows that beneﬁcial QoL changes occur after
MR-guided HIFU treatment, in addition to improvements in
pain, which indicate even greater responses to treatment
than when assessed using pain criteria alone. Physical
function and symptoms, including appetite loss, fatigue,
insomnia and constipation, were improved across the
whole cohort, reﬂecting the importance of monitoring the
individual elements that constitute QoL when considering
patient outcome. With an increasing number of cancer
survivors, the control of metastatic bone pain is critical in
maintaining QoL, making interventions that achieve this
(such as MR-guided HIFU) of paramount importance.
The reduction in pain scores measured by the BPI-SF and
the QLQ-C15-PAL were associated with an increase in
physical functionality as assessed by the QLQ-C15-PAL, and
further corroborated by the functional interference scale in
the QLQ-BM22. Improved physical functioning may
improve the patients’ ability to complete activities that are a
part of daily life. The slight worsening of scores in the
physical functioning scale for both responders and non-
responders at day 30 (compared with later post-treatment
time points) was unexpected. These patterns remainedFig 2. Graphs representing changes between responders and non-respon
The vertical axis is the mean score and the horizontal axis is the study t
scores represent diminished symptoms, i.e. increased quality of life.
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doi.org/10.1016/j.clon.2017.12.023even when accounting for patients who withdrew from the
study before day 90. It is hard to draw ﬁrm conclusions on
the reason for this from our small cohort. However, one
theory relates to bone weakness, which, pre-clinical studies
have shown to occur after MR-guided HIFU, predominantly
4e6 weeks after treatment, returning to normal levels at 3
months [25,26]. As bone weakness is known to have a sig-
niﬁcant effect on physical functioning [27] this could be a
possible explanation. Fortunately, no post-treatment frac-
tures occurred in our group, although this remains a theo-
retical risk.
Although the clinically signiﬁcant reductions in fatigue,
appetite loss and nausea and vomiting may be as a direct
result of improvement in pain scores, there could also be an
indirect effect through a reduction in analgesic intake as a
result of reduced pain. Also, although the initial low score of
w26 for constipation may be subject to ﬂoor effects, the
mean changes show responders consistently experienced at
least a 57% improvement in constipation symptoms from
day 14 onwards, indicating that a reduction in opioid
analgesic consumption caused this improvement [28,29].
This feature has been reported previously as signiﬁcantly
reducing QoL [30]. Conversely, non-responders experienced
no clinically signiﬁcant improvements for any of the
symptoms at any of the time points. Dyspnoea remained
unaffected, as it is not associated with bone metastases.
Even in the presence of concurrent pulmonary metastases,
treatment of bone pain would not be expected to affect
dyspnoea.
Interestingly both the emotional functioning and psy-
chosocial aspects scales remained relatively stable, sug-
gesting that improvement in other aspects of QoL was
insufﬁcient to constitute an improvement in emotional
functioning. This is to be expected in end-stage patients
with extensive metastatic disease. In fact, the end-stage
nature of this cohort needs to be considered; 17% of pa-
tients died during the study. It is therefore reassuring that at
a time when QoL would usually be worsening [4,31], it is
possible with a non-invasive single treatment to improve
overall QoL for many patients within a 3 month time frame,
by reducing pain and analgesic use and thus improving
physical functioning to allow self-care activities.
The response for the purposes of this QoL assessment
was based on classiﬁcation at day 30, as this was deter-
mined a priori as the primary end point for measuring pain
response. However, this did not reﬂect the changing re-
sponses some patients experienced throughout the study.
In fact, 27% of patients who remained in the study until day
90 would have been classiﬁed differently then, compared
with their classiﬁcation at day 30. This may explain why the
pain scale of the QLQ-C15-PAL and the painful characteris-
tics scale of the QLQ-BM22 decreased to a similar level in
responders and non-responders by the study end. In our
small cohort, the assessment of pain and QoL may have
been better classiﬁed later than 30 days after treatment.ders in each QLQ-BM22 and QLQ-C15-PAL symptom scale over time.
ime point. Error bars show standard error of the mean (SEM). Lower
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Table 3
Mean change scores compared with baseline
Responders Non-responders
Day 7 Day 14 Day 30 Day 60 Day 90 Day 7 Day 14 Day 30 Day 60 Day 90
QLQ-C15-PAL
Fatigue* e7.43 e14.84z e9.90 e23.65z e21.01z 8.56 e1.18 11.34 5.31 3.82
Appetite loss* e18.52z e18.52z e18.52z e23.81z e33.33z 0.00 e12.5 12.50 e16.67 e13.33
Nausea and vomiting* e1.86 e9.27 e3.71 e11.91 e16.68 z 0.00 0.00 8.31 e4.87 e10.44
Constipation* 0.00 e14.81 e22.22 z e16.40 e14.81 5.36 13.69 9.52 e7.14 9.52
Pain* e14.82z e20.37z e24.07z e31.48z e25.93z 4.17 0.00 6.25 e3.47 e21.25z
Emotional functioningy e3.70 e0.92 7.40 7.02 6.02 e8.03 e10.10 e5.94 e4.58 e4.29
Physical functioningy 11.11 13.33z 8.14 13.96z 22.21z 0.81 0.83 e11.66x e6.12 e1.02
QLQ-BM22
Painful sites* e10.62z e15.56z e14.07z e11.64z e10.37z 7.22 e0.60 3.33 1.94 5.50
Painful characteristics* e15.43z e14.82z e16.05z e21.52z e13.58z 13.82x 10.64 10.24 5.61 e8.09
Functional interferencey 11.57z 16.73z 12.43z 23.80z 21.36z 6.51 3.28 e4.24 e1.46 8.44
Psychosocial aspectsy 4.32 3.55 e1.85 3.35 2.16 6.94 5.85 e0.70 e1.16 e0.97
Scores above the minimal clinically important differences (MCIDs) set by Raman et al. [24] are highlighted in bold. No MCIDs available for
the dyspnoea, insomnia and overall quality of life scales.
* Increasing scores represent worsening quality of life.
y Increasing scores represent improving quality of life.
z Clinically signiﬁcant improvement.
x Clinically signiﬁcant deterioration.
D. Harding et al. / Clinical Oncology xxx (2017) 1e108Although this observation might not be generalisable, it
does indicate a need for longer-term follow-up. In our
experience, the duration of improvements in pain and QoL
in all participants after a single treatment was highly
encouraging.
As in some other studies [12], all our patients had
received previous EBRT to their painful bone metastasis
and, therefore, it was not possible to compare the effect on
QoL between patients with and without previous EBRT
treatment. A QoL assessment has not been conducted pre-
viously in radiation naive patients, in whom pain response
rates to HIFU of 89% (with 72% of patients experiencing
complete pain relief) have been reported [32]. These pain
response rates are noticeably higher than in EBRT refractory
patients, indicating that MR-guided HIFU may well have an
even greater impact on QoL if given as an initial palliative
option. However, as EBRT is the current standard of care for
patients referred with localised bone pain, it would be
beneﬁcial to directly compare QoL outcomes in patients
receiving EBRT and MR-guided HIFU for metastatic bone
pain, to determine which method has the greatest impact
on QoL. Although our study can be compared with those
using the same QoL measures to examine the impact of
EBRT on QoL [33], variations in trial methodologies make
comparison of the two treatments difﬁcult. A phase III
randomised controlled trial (NCT01091883) [34] is currently
underway that aims to assess safety, pain and QoL outcomes
in patients receiving MR-guided HIFU or EBRT. Greater un-
derstanding of any pain and QoL differences after MR-
guided HIFU or EBRT will be helpful in determining the
optimal treatment pathways for patients with localised
painful bone metastases.
By using the QLQ-C15-PAL, a palliative-speciﬁc ques-
tionnaire, we have been able to determine a variety of
symptom and functional changes that can be easilyPlease cite this article in press as: Harding D, et al., Evaluation of Quality
with Magnetic Resonance-guided High Intensity Focused Ultrasound: A
doi.org/10.1016/j.clon.2017.12.023interpreted from a clinical perspective. In addition, using
the QLQ-BM22, a bone metastasis-speciﬁc questionnaire,
we have been able to reliably assess a range of QoL issues
that are the most pertinent for patients with bone me-
tastases. However, both questionnaires have limitations.
Neither questionnaire measures spiritual components,
which have been found to be equally important to physical
symptoms for QoL [35]. Although it could be beneﬁcial to
add further questions assessing this issue, this would risk
placing an additional burden on patients. The small sample
size is another limitation of this study and the large
standard deviations made it inappropriate to carry out
relevant statistical tests. This is a particular issue for sub-
jective and qualitative assessments such as QoL and future
studies would beneﬁt from larger sample sizes. However,
evaluation of clinical signiﬁcance through MCIDs provides
evidence for the improvements in QoL seen among
responders.Conclusion
Our data show that patients with disseminated malig-
nancy and focal metastatic bone pain, refractory to pallia-
tive radiotherapy, can experience substantial QoL
improvements after a single MR-guided HIFU treatment.
We observed improvements in both pain and physical
functioning, which may have been related to decreased
reliance on analgesics, with subsequent reduction in their
side-effects. We did not observe any treatment-related
serious adverse effects. Further studies that will evaluate
QoL outcomes in treatment-naïve patients undergoing
either EBRT or MR-guided HIFU will be important in
determining the optimal treatment pathways for patients
with painful bone metastases.of Life Outcomes Following Palliative Treatment of Bone Metastases
n International Multicentre Study, Clinical Oncology (2017), https://
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